Literature DB >> 27784796

Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Laura A VanBlargan1, Leslie Goo2, Theodore C Pierson2.   

Abstract

The antibody response plays a key role in protection against viral infections. While antiviral antibodies may reduce the viral burden via several mechanisms, the ability to directly inhibit (neutralize) infection of cells has been extensively studied. Eliciting a neutralizing-antibody response is a goal of many vaccine development programs and commonly correlates with protection from disease. Considerable insights into the mechanisms of neutralization have been gained from studies of monoclonal antibodies, yet the individual contributions and dynamics of the repertoire of circulating antibody specificities elicited by infection and vaccination are poorly understood on the functional and molecular levels. Neutralizing antibodies with the most protective functionalities may be a rare component of a polyclonal, pathogen-specific antibody response, further complicating efforts to identify the elements of a protective immune response. This review discusses advances in deconstructing polyclonal antibody responses to flavivirus infection or vaccination. Our discussions draw comparisons to HIV-1, a virus with a distinct structure and replication cycle for which the antibody response has been extensively investigated. Progress toward deconstructing and understanding the components of polyclonal antibody responses identifies new targets and challenges for vaccination strategies.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27784796      PMCID: PMC5116878          DOI: 10.1128/MMBR.00024-15

Source DB:  PubMed          Journal:  Microbiol Mol Biol Rev        ISSN: 1092-2172            Impact factor:   11.056


  297 in total

1.  HIV-1 nomenclature proposal.

Authors:  D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

2.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

3.  Structure of West Nile virus.

Authors:  Suchetana Mukhopadhyay; Bong-Suk Kim; Paul R Chipman; Michael G Rossmann; Richard J Kuhn
Journal:  Science       Date:  2003-10-10       Impact factor: 47.728

4.  Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody.

Authors:  Mickaël V Cherrier; Bärbel Kaufmann; Grant E Nybakken; Shee-Mei Lok; Julia T Warren; Beverly R Chen; Christopher A Nelson; Victor A Kostyuchenko; Heather A Holdaway; Paul R Chipman; Richard J Kuhn; Michael S Diamond; Michael G Rossmann; Daved H Fremont
Journal:  EMBO J       Date:  2009-08-27       Impact factor: 11.598

5.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

6.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

7.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

8.  DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.

Authors:  Guntur Fibriansah; Kristie D Ibarra; Thiam-Seng Ng; Scott A Smith; Joanne L Tan; Xin-Ni Lim; Justin S G Ooi; Victor A Kostyuchenko; Jiaqi Wang; Aravinda M de Silva; Eva Harris; James E Crowe; Shee-Mei Lok
Journal:  Science       Date:  2015-07-03       Impact factor: 47.728

9.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

10.  The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin.

Authors:  Bargavi Thyagarajan; Jesse D Bloom
Journal:  Elife       Date:  2014-07-08       Impact factor: 8.140

View more
  34 in total

1.  Basic Amino Acid Substitution at Residue 367 of the Envelope Protein of Tembusu Virus Plays a Critical Role in Pathogenesis.

Authors:  Mengxu Sun; Lijiao Zhang; Yanxin Cao; Jun Wang; Ziding Yu; Xue Sun; Fengli Liu; Zhuolin Li; Pinghuang Liu; Jingliang Su
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

Review 2.  Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19.

Authors:  Ming Hao; Dongxu Wang; Qianyun Xia; Shaoning Kan; Lu Chang; Huimin Liu; Zhijing Yang; Weiwei Liu
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

3.  Indoleamine 2,3-dioxygenase 1 is essential for sustaining durable antibody responses.

Authors:  Shivana M Lightman; Jennifer L Peresie; Louise M Carlson; G Aaron Holling; Mackenzie M Honikel; Colin A Chavel; Michael J Nemeth; Scott H Olejniczak; Kelvin P Lee
Journal:  Immunity       Date:  2021-11-16       Impact factor: 43.474

4.  Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.

Authors:  Rita E Chen; Brittany K Smith; John M Errico; David N Gordon; Emma S Winkler; Laura A VanBlargan; Chandni Desai; Scott A Handley; Kimberly A Dowd; Emerito Amaro-Carambot; M Jane Cardosa; Carlos A Sariol; Esper G Kallas; Rafick-Pierre Sékaly; Nikos Vasilakis; Daved H Fremont; Stephen S Whitehead; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2021-10-04       Impact factor: 31.316

5.  A perspective on potential antibody-dependent enhancement of SARS-CoV-2.

Authors:  Ann M Arvin; Katja Fink; Michael A Schmid; Andrea Cathcart; Roberto Spreafico; Colin Havenar-Daughton; Antonio Lanzavecchia; Davide Corti; Herbert W Virgin
Journal:  Nature       Date:  2020-07-13       Impact factor: 49.962

Review 6.  The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.

Authors:  Félix A Rey; Karin Stiasny; Marie-Christine Vaney; Mariano Dellarole; Franz X Heinz
Journal:  EMBO Rep       Date:  2017-12-27       Impact factor: 8.807

7.  Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.

Authors:  Sabra L Klein; Andrew Pekosz; Han-Sol Park; Rebecca L Ursin; Janna R Shapiro; Sarah E Benner; Kirsten Littlefield; Swetha Kumar; Harnish Mukesh Naik; Michael J Betenbaugh; Ruchee Shrestha; Annie A Wu; Robert M Hughes; Imani Burgess; Patricio Caturegli; Oliver Laeyendecker; Thomas C Quinn; David Sullivan; Shmuel Shoham; Andrew D Redd; Evan M Bloch; Arturo Casadevall; Aaron Ar Tobian
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

8.  High-resolution asymmetric structure of a Fab-virus complex reveals overlap with the receptor binding site.

Authors:  Daniel J Goetschius; Samantha R Hartmann; Lindsey J Organtini; Heather Callaway; Kai Huang; Carol M Bator; Robert E Ashley; Alexander M Makhov; James F Conway; Colin R Parrish; Susan L Hafenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

9.  Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection.

Authors:  Sherif A El-Kafrawy; Aymn T Abbas; Sayed S Sohrab; Ashraf A Tabll; Ahmed M Hassan; Naoko Iwata-Yoshikawa; Noriyo Nagata; Esam I Azhar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-26

Review 10.  Dengue mouse models for evaluating pathogenesis and countermeasures.

Authors:  Rita E Chen; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2020-09-17       Impact factor: 7.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.